Developer docs
API playgroundTry for free, no card

Search company profiles

FatiAbGen Inc.

Full company profile

uuid0003fia

Namestring
FatiAbGen Inc.
Legal namestring
FatiAbGen Co., Ltd.
Websiteurl
fatiabgen.com
Company typeenum
Private
Founded yearint
2020
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersSejung, South Korea
HQ citystring
Sejung
HQ countrystring
South Korea
HQ regionstring
Asia
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
monoclonal antibody therapy, antibody drug conjugates, bispecific antibody development, oncology drug development, immunology therapeutics
Industry3 codes
PRIMARYHLAAAAAA
Monoclonal Antibody Therapeutics (mAbs)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAAAE
Antibody-Drug Conjugates (ADCs) & Antibody Conjugates
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAAAF
Bispecific & Multispecific Antibodies
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Biopharmaceuticals
No data
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Pipeline Development and Licensing
TypeLicensing Royalties
Description

As a pre-revenue biotech company, FatiAbGen is focused on discovering and developing innovative monoclonal antibody-based therapies. Revenue is expected to come from licensing deals, co-development partnerships, and ultimately product commercialization in oncology and immunology.

fatiabgen.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

FatiAbGen is a pre-clinical biopharmaceutical company that uses a proprietary antibody engineering platform to discover and develop multi-modality monoclonal antibody-based therapies, including Antibody Drug Conjugates (ADCs) and T Cell-engager bispecific antibodies, targeting oncology and immunology/allergy diseases. The company's lead asset is a superior anti-mesothelin ADC with strong pre-clinical data. FatiAbGen pursues revenue through licensing deals, co-development partnerships with pharma/biotech firms, and academic collaborations.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Selected as 2023 The 3rd Korea Drug Development Project
+1 more record
Product overview1 text field

FatiAbGen Inc. is an antibody-based platform company developing multi-modality antibodies for difficult targets in high unmet need diseases in oncology and immunology. The company's portfolio consists of three core areas: ADC (Antibody Drug Conjugates) platform including a lead anti-mesothelin ADC asset with strong pre-clinical data, an Autoimmune Disease Treatment Platform leveraging best-in-class therapeutic antibodies for allergy and immunological disorders, and a Pipeline Assets program for Oncology and Allergy disease treatments. The company operates using its own therapeutic antibody technology platforms and pursues open innovation with external collaborations.

Product and service4 records
1Antibody Drug Conjugate (ADC) Platform
CategoryAntibody Therapeutics - Oncology
Description

Proprietary Antibody Drug Conjugate platform for targeted cancer therapy, including the lead anti-mesothelin ADC asset. Designed to be licensed or co-developed with pharmaceutical and biotech partners for solid tumor indications.

2Anti-Mesothelin ADC (Lead Asset)
CategoryAntibody Drug Conjugate - Oncology
Description

Superior anti-mesothelin ADC lead candidate targeting mesothelin-expressing solid tumors with high unmet medical need. Currently in pre-clinical stage.

3Autoimmune and Allergy Disease Treatment Platform
CategoryAntibody Therapeutics - Immunology/Allergy
Description

Therapeutic antibody-based treatments for autoimmune diseases and allergy conditions, leveraging FatiAbGen's proprietary best-in-class therapeutic antibodies and in-licensed technology from Ajou University.

4Pre-Clinical Pipeline Assets (Oncology and Allergy)
CategoryAntibody Therapeutics Pipeline
Description

Broad pre-clinical antibody pipeline spanning oncology and allergy disease targets, available for licensing and co-development with pharmaceutical and biotech partners.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierMinorTypeOthersAnnounced on2024-02-01
Description

FatiAbGen International GmbH is located at the Switzerland Innovation Park Basel Area AG, joining the Novartis Campus and Basel area life sciences ecosystem.

Strategic tierMinorTypeOthersAnnounced on2024-02-01
Description

Support organizations that assisted FatiAbGen in establishing its European subsidiary in Basel, Switzerland.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-04-20
Description

FatiAbGen and Y-Biologics signed a collaborative R&D term sheet for discovery and co-development of antibody candidates for targets of various cancers. Y-Biologics focuses on novel antibody therapeutics using its human antibody library Ymax-ABL and bispecific antibody platform ALiCE. The collaboration is expected to bolster new discovery and accelerate R&D progress for both companies.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-04-12
Description

FatiAbGen and Chonnam National University agreed on joint R&D collaboration to discover novel target cancer cells and build a toxin library, based on bioinformatics.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-03-08
Description

FatiAbGen and Wonkwang University agreed on joint R&D collaboration for discovery of new toxin peptide to cure various cancers.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Clinical-stage biotech using AI-driven antibody discovery to develop mono- and bispecific oncology therapeutics; overlaps with FatiAbGen's antibody engineering and bispecific programs.

TypeDirect peer
Description

Clinical-stage antibody therapeutics company focused on ADCs and immuno-oncology; a direct comparand and current research collaboration partner of FatiAbGen.

TypeDirect peer
Description

Korean biotech developing ADC platforms including linker and payload chemistry; an existing research collaboration partner of FatiAbGen and a directly comparable ADC-platform peer.

TypeDirect peer
Description

Korean antibody discovery company with a human antibody library and bispecific platform (ALiCE); an active co-development partner of FatiAbGen and a closely comparable antibody-platform peer.

TypeEmerging player
Description

Clinical-stage company developing next-generation ADCs for solid tumors; comparable to FatiAbGen's lead anti-mesothelin ADC ambition and ADC platform focus.

TypeEmerging player
Description

Clinical-stage ADC developer with proprietary linker and payload platforms targeting oncology; comparable in modality (ADCs) and target indications to FatiAbGen.

TypeBroad incumbent
Description

Established ADC pioneer (Elahere for ovarian cancer) now part of AbbVie; sets the standard for ADC commercial economics and represents a likely acquirer/partner for emerging ADC biotechs like FatiAbGen.

TypeBroad incumbent
Description

Global antibody therapeutics company with validated bispecific platforms (e.g., bispecific T-cell engagers); overlaps directly with FatiAbGen's T-cell engager and bispecific antibody programs.

9Atreca
TypeEmerging player
Description

Clinical-stage biotech developing novel antibody-based immunotherapies derived from patient immune responses; comparable in being an antibody-discovery platform company pursuing oncology partnerships.

10Mythic Therapeutics
TypeEmerging player
Description

Clinical-stage ADC developer with a focus on solid tumors; comparable in therapeutic area (oncology ADCs) and stage of development to FatiAbGen's lead program.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

FatiAbGen Inc.

Biopharmaceuticalsfatiabgen.com

FatiAbGen Inc. firmographics

Firmographics
Name
FatiAbGen Inc.
Legal name
FatiAbGen Co., Ltd.
Website
https://fatiabgen.com
Company type
Private
Founded year
2020
Operating status
Operating
Headcount range
1–10 employees
Ownership category
akta.pro rank

FatiAbGen Inc. industry classification

Industry
Product category
Biopharmaceuticals
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAAAA
Monoclonal Antibody Therapeutics (mAbs)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAAAE
Antibody-Drug Conjugates (ADCs) & Antibody Conjugates
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAAAF
Bispecific & Multispecific Antibodies
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)

Keywords

  • Monoclonal antibody therapy
  • Antibody drug conjugates
  • Bispecific antibody development
  • Oncology drug development
  • Immunology therapeutics

Where FatiAbGen Inc. is headquartered

Location

Headquarters

HQ city
Sejung
HQ country
South Korea
HQ region
Asia

Offices2 records

Markets served

FatiAbGen Inc. business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Pipeline Development and Licensing: As a pre-revenue biotech company, FatiAbGen is focused on discovering and developing innovative monoclonal antibody-based therapies. Revenue is expected to come from licensing deals, co-development partnerships, and ultimately product commercialization in oncology and immunology.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels3 records

FatiAbGen Inc. product offering

Product offering

Core offering

FatiAbGen is a pre-clinical biopharmaceutical company that uses a proprietary antibody engineering platform to discover and develop multi-modality monoclonal antibody-based therapies, including Antibody Drug Conjugates (ADCs) and T Cell-engager bispecific antibodies, targeting oncology and immunology/allergy diseases. The company's lead asset is a superior anti-mesothelin ADC with strong pre-clinical data. FatiAbGen pursues revenue through licensing deals, co-development partnerships with pharma/biotech firms, and academic collaborations.

Product overview

FatiAbGen Inc. is an antibody-based platform company developing multi-modality antibodies for difficult targets in high unmet need diseases in oncology and immunology. The company's portfolio consists of three core areas: ADC (Antibody Drug Conjugates) platform including a lead anti-mesothelin ADC asset with strong pre-clinical data, an Autoimmune Disease Treatment Platform leveraging best-in-class therapeutic antibodies for allergy and immunological disorders, and a Pipeline Assets program for Oncology and Allergy disease treatments. The company operates using its own therapeutic antibody technology platforms and pursues open innovation with external collaborations.

Differentiator

Problem solved

Functional benefit

Products and services

  • Antibody Drug Conjugate (ADC) Platform Proprietary Antibody Drug Conjugate platform for targeted cancer therapy, including the lead anti-mesothelin ADC asset. Designed to be licensed or co-developed with pharmaceutical and biotech partners for solid tumor indications.
  • Anti-Mesothelin ADC (Lead Asset) Superior anti-mesothelin ADC lead candidate targeting mesothelin-expressing solid tumors with high unmet medical need. Currently in pre-clinical stage.
  • Autoimmune and Allergy Disease Treatment Platform Therapeutic antibody-based treatments for autoimmune diseases and allergy conditions, leveraging FatiAbGen's proprietary best-in-class therapeutic antibodies and in-licensed technology from Ajou University.
  • Pre-Clinical Pipeline Assets (Oncology and Allergy) Broad pre-clinical antibody pipeline spanning oncology and allergy disease targets, available for licensing and co-development with pharmaceutical and biotech partners.

Quantifiable outcome

  • Selected as 2023 The 3rd Korea Drug Development Project
  • +1 more outcomes

Companies that use FatiAbGen Inc.

Customer profile

Segments2 records

Ideal customer profiles1 record

FatiAbGen Inc. technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

FatiAbGen Inc. partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered minor and core.

  • Switzerland Innovation Park Basel Area AGminorOthers · 1 February 2024FatiAbGen International GmbH is located at the Switzerland Innovation Park Basel Area AG, joining the Novartis Campus and Basel area life sciences ecosystem.
  • Swiss Business Hub Korea / Switzerland Global Enterprise / Basel Area Business and InnovationminorOthers · 1 February 2024Support organizations that assisted FatiAbGen in establishing its European subsidiary in Basel, Switzerland.
  • Y-Biologics Inc.coreStrategic or Co-development Partner · 20 April 2021FatiAbGen and Y-Biologics signed a collaborative R&D term sheet for discovery and co-development of antibody candidates for targets of various cancers. Y-Biologics focuses on novel antibody therapeutics using its human antibody library Ymax-ABL and bispecific antibody platform ALiCE. The collaboration is expected to bolster new discovery and accelerate R&D progress for both companies.
  • Chonnam National UniversitycoreStrategic or Co-development Partner · 12 April 2021FatiAbGen and Chonnam National University agreed on joint R&D collaboration to discover novel target cancer cells and build a toxin library, based on bioinformatics.
  • Wonkwang UniversitycoreStrategic or Co-development Partner · 8 March 2021FatiAbGen and Wonkwang University agreed on joint R&D collaboration for discovery of new toxin peptide to cure various cancers.

Scale indicators4 records

Recent moves8 records

Expansion highlights5 records

FatiAbGen Inc. competitors and assessment

Company assessment

Emerging players

  • Adagene: Clinical-stage biotech using AI-driven antibody discovery to develop mono- and bispecific oncology therapeutics; overlaps with FatiAbGen's antibody engineering and bispecific programs.
  • ProfoundBio: Clinical-stage company developing next-generation ADCs for solid tumors; comparable to FatiAbGen's lead anti-mesothelin ADC ambition and ADC platform focus.
  • Mersana Therapeutics: Clinical-stage ADC developer with proprietary linker and payload platforms targeting oncology; comparable in modality (ADCs) and target indications to FatiAbGen.
  • Atreca: Clinical-stage biotech developing novel antibody-based immunotherapies derived from patient immune responses; comparable in being an antibody-discovery platform company pursuing oncology partnerships.
  • Mythic Therapeutics: Clinical-stage ADC developer with a focus on solid tumors; comparable in therapeutic area (oncology ADCs) and stage of development to FatiAbGen's lead program.

Direct peers

  • Pyxis Oncology: Clinical-stage antibody therapeutics company focused on ADCs and immuno-oncology; a direct comparand and current research collaboration partner of FatiAbGen.
  • LegoChem Biosciences: Korean biotech developing ADC platforms including linker and payload chemistry; an existing research collaboration partner of FatiAbGen and a directly comparable ADC-platform peer.
  • Y-Biologics: Korean antibody discovery company with a human antibody library and bispecific platform (ALiCE); an active co-development partner of FatiAbGen and a closely comparable antibody-platform peer.

Broad incumbents

  • ImmunoGen (now AbbVie): Established ADC pioneer (Elahere for ovarian cancer) now part of AbbVie; sets the standard for ADC commercial economics and represents a likely acquirer/partner for emerging ADC biotechs like FatiAbGen.
  • Genmab: Global antibody therapeutics company with validated bispecific platforms (e.g., bispecific T-cell engagers); overlaps directly with FatiAbGen's T-cell engager and bispecific antibody programs.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

FatiAbGen Inc. financial estimates

Financial estimate

Revenue estimate

Valuation estimate

FatiAbGen Inc. leadership team

Management profile

Number of profiles

Profiles5 records

FatiAbGen Inc. subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

FatiAbGen Inc. funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

FatiAbGen Inc. M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about FatiAbGen Inc.

What does FatiAbGen Inc. do?

FatiAbGen is a pre-clinical biopharmaceutical company that uses a proprietary antibody engineering platform to discover and develop multi-modality monoclonal antibody-based therapies, including Antibody Drug Conjugates (ADCs) and T Cell-engager bispecific antibodies, targeting oncology and immunology/allergy diseases. The company's lead asset is a superior anti-mesothelin ADC with strong pre-clinical data. FatiAbGen pursues revenue through licensing deals, co-development partnerships with pharma/biotech firms, and academic collaborations.

Is FatiAbGen Inc. a public or private company?

FatiAbGen Inc. is a private company. It is classified as venture growth investor backed and is currently operating.

When was FatiAbGen Inc. founded?

FatiAbGen Inc. was founded in 2020. It employs 1 to 10 people.

Where is FatiAbGen Inc. based?

FatiAbGen Inc. is headquartered in Sejung, South Korea, in the Asia region.

How does FatiAbGen Inc. make money?

One revenue line is on record: pipeline Development and Licensing.

Who are FatiAbGen Inc.'s main competitors?

Emerging players on record are Adagene, ProfoundBio, Mersana Therapeutics, Atreca and Mythic Therapeutics. Direct peers are Pyxis Oncology, LegoChem Biosciences and Y-Biologics. Broad incumbents are ImmunoGen (now AbbVie) and Genmab.

Does FatiAbGen Inc. have an API?

No public API is recorded for FatiAbGen Inc..

What industry is FatiAbGen Inc. in?

FatiAbGen Inc.'s product category is Biopharmaceuticals. Its primary akta.pro industry code is HLAAAAAA, Monoclonal Antibody Therapeutics (mAbs), with a secondary code of HLAAAAAE, Antibody-Drug Conjugates (ADCs) & Antibody Conjugates. Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals